BDFS Capital’s AbbVie ABBV Stock Holding History

BDFS Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$226K	Buy	+899	New	+$193K	0.1%	111
2026 Q1	–	Sell	-889	Closed	-$203K	–	138
2025 Q4	$203K	Buy	+889	New	+$203K	0.1%	133

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BDFS Capital's ABBV Position: Q2 2026 in Review

BDFS Capital opened a new position in AbbVie (ABBV) in Q2 2026: 899 shares worth $226K. The stake represents 0.1% of the portfolio and ranks #111 among its holdings. This is a return to the name: BDFS Capital previously reported a position in ABBV as recently as Q4 2025.

BDFS Capital first reported a position in ABBV in Q4 2025 and has held it in 2 quarters since. 4,187 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

BDFS Capital held 899 shares of AbbVie worth $226K as of Q2 2026.
AbbVie was a new BDFS Capital position in Q2 2026.
AbbVie made up 0.1% of BDFS Capital's portfolio in Q2 2026, its #111 holding.
BDFS Capital first reported a position in AbbVie in Q4 2025 and has held it in 2 quarters since.
4,187 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on BDFS Capital's 13F filing for Q2 2026, filed 15 Jul 2026.